Table 1.
Baseline demographics.
| Coronavirus |
Influenza |
p-value |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Total* (n = 495) |
AC** (n = 65) |
No AC** (n = 430) |
Total* (n = 429) |
AC*** (n = 56) |
No AC*** (n = 373) |
* | ** | *** | |
| Age (years) | 67 (52, 77) |
75 (67, 84) |
65 (50, 76) |
62 (44, 73) |
73 (60, 78) |
60 (40, 71) |
<0.001 | <0.001 | <0.001 |
| Sex | |||||||||
| Female | 256 (52%) | 33 (51%) | 223 (52%) | 236 (55%) | 29 (52%) | 207 (56%) | 0.31 | 0.87 | 0.60 |
| Ethnicity | |||||||||
| Caucasian African American Other |
291 (59%) 164 (33%) 40 (8%) |
43 (66%) 20 (31) 2 (3%) |
248 (58%) 144 (34%) 38 (9%) |
289 (67%) 115 (27%) 25 (6%) |
45 (80%) 9 (16%) 2 (4%) |
244 (65%) 106 (28%) 23 (6%) |
0.01 | 0.10 | 0.04 |
| BMI (kg/m2) | 29 (23.9, 35.4) |
27.5 (21.5, 34.4) |
29.2 (24.2, 35.4) |
29.1 (24.2, 34.9) |
28.5 (24.3, 36.5) |
29.3 (24.2, 34.9) |
0.48 | 0.27 | 0.91 |
| Smoking Active Former Never |
|||||||||
| 40 (8%) 191 (39%) 264 (53%) |
5 (8%) 31 (48%) 29 (45%) |
37 (8%) 160 (37%) 233 (54%) |
89 (21%) 175 (41%) 165 (39%) |
7 (13%) 31 (55%) 18 (32%) |
82 (22%) 144 (39%) 147 (39%) |
<0.001 | 0.48 | 0.84 | |
| COPD | 83 (17%) | 16 (25%) | 67 (16%) | 120 (28%) | 16 (29%) | 104 (28%) | <0.001 | 0.07 | 0.91 |
| Dementia | 71 (14%) | 16 (25%) | 55 (13%) | 19 (4%) | 4 (7%) | 15 (4%) | <0.001 | 0.01 | 0.29 |
| OSA | 71 (14%) | 16 (25%) | 55 (13%) | 77 (18%) | 14(25%) | 63 (17%) | 0.14 | 0.01 | 0.14 |
| DM | 188 (38%) | 28 (43%) | 160 (37%) | 143 (33%) | 24 (43%) | 119 (32%) | 0.14 | 0.36 | 0.10 |
| VTE history | 42 (9%) | 26 (40%) | 16 (4%) | 36 (8%) | 17 (30%) | 19 (5%) | 0.96 | <0.001 | <0.001 |
| Atrial Fib | 93 (19%) | 41 (63%) | 52 (12%) | 92 (21%) | 42 (75%) | 50 (13%) | 0.31 | <0.001 | <0.001 |
| HFpEF/HFrEF | 78 (16%) | 25 (39%) | 53 (12%) | 71 (17%) | 21 (38%) | 50 (13%) | 0.88 | <0.001 | <0.001 |
| CAD | 91 (18%) | 20 (31%) | 71 (17%) | 77 (18%) | 19 (34%) | 58 (16%) | 0.86 | 0.006 | <0.001 |
| HTN | 329 (67%) | 55 (85%) | 274 (64%) | 276 (64%) | 50 (89%) | 226 (61%) | 0.49 | 0.007 | <0.001 |
| CKD | 117 (24%) | 34 (34%) | 95 (22%) | 97 (23%) | 16 (29%) | 81 (22%) | 0.71 | 0.03 | 0.25 |
| Immunosuppression | 39 (8%) | 6 (9%) | 33 (8%) | 33 (8%) | 4 (7%) | 29 (8%) | 0.31 | 0.67 | 0.87 |
| Anticoagulation Oral Xa inhibitor VKA DTI LMWH |
65 (13%) 38 24 1 2 |
38 24 1 2 |
56 (13%) 31 20 2 3 |
31 20 2 3 |
0.46 | ||||
Anticoagulation (AC), Body Mass Index (BMI), Chronic Obstructive Pulmonary Disease (COPD), Obstructive Sleep Apnea (OSA), Diabetes Mellitus (DM), Venous Thromboembolism (VTE), Heart Failure Preserved Ejection Fraction (HFpEF), Heart Failure Reduced Ejection Fraction (HFrEF), Coronary Artery Disease (CAD), Hypertension HTN), Chronic Kidney Disease (CKD), Vitamin K Antagonist (VKA), Direct Thrombin Inhibitor (DTI), Low Molecular Weight Heparin (LMWH).